MISSISSAUGA, ON, June 14,
2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH)
(OTCQX: CPHRF) ("Cipher" or the "Company") today
announced that it held its annual and special meeting of
shareholders earlier today and that all matters put forward before
shareholders for consideration and approval as set out in the
Company's management information circular dated May 3, 2024 were approved by the requisite
majority of votes cast at the meeting. In particular, shareholders
approved the election of all director nominees, the re-approval of
RSM Canada LLP as auditor of the Company, the resolution approving
the unallocated options, rights and other entitlements under the
Company's stock option plan and the resolution approving the
unallocated awards, rights and other entitlements under the
Company's performance and restricted share unit plan. A total of
approximately 14 million shares, representing 58.1% of the total
shares outstanding were represented in person or by proxy at the
meeting. The detailed results of the vote for the election of
directors of Cipher is set out below:
|
Nominee
|
Votes
For
|
% Votes
For
|
Votes
Withheld
|
% Votes
Withheld
|
|
Craig Mull
|
12,526,885
|
92.35 %
|
1,038,281
|
7.65 %
|
|
Harold
Wolkin
|
12,523,585
|
92.32 %
|
1,041,581
|
7.68 %
|
|
Douglas
Deeth
|
13,536,822
|
99.79 %
|
28,344
|
0.21 %
|
|
Hubert
Walinski
|
13,452,822
|
99.17 %
|
112,344
|
0.83 %
|
About Cipher Pharmaceuticals
Inc.
Cipher Pharmaceuticals (TSX:CPH) (OTCQX:CPHRF) is a specialty
pharmaceutical company with a robust and diversified portfolio of
commercial and early to late-stage products. Cipher acquires
products that fulfill unmet medical needs, manages the required
clinical development and regulatory approval process, and currently
markets those products either directly in Canada or indirectly through partners in
Canada, the U.S., and South America. For more information,
visit www.cipherpharma.com.
SOURCE Cipher Pharmaceuticals Inc.